<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766803</url>
  </required_header>
  <id_info>
    <org_study_id>PoznanUMS 3</org_study_id>
    <nct_id>NCT02766803</nct_id>
  </id_info>
  <brief_title>Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients</brief_title>
  <official_title>Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poznan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Poznan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is the most common endocrinopathy affecting women of
      reproductive age. Hyperandrogenism is the central feature of PCOS. Studies on isolated
      ovarian theca-interstitial cells indicate that resveratrol, a natural polyphenol, reduces
      androgen production.

      This study is designed to evaluate the endocrine and metabolic effects of simvastatin and
      resveratrol on PCOS.

      Methods: A randomized (1:1) double-blind, placebo-controlled trial will evaluate the effects
      of administering 20 mg of simvastatin daily and 500 mg of resveratrol daily, or administering
      20 mg simvastatin and the placebo to women with PCOS at an academic hospital. PCOS is defined
      according to the Rotterdam criteria. Evaluations are performed at baseline and repeated after
      3 and 6 months of treatment. The main outcome is a change of the serum total testosterone and
      the fasting insulin level.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>testosterone serum concentration</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>PCOS, Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Simvastatin + resveratrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>simvastatin 20 mg daily micronized trans-resveratrol 500 mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>simvastatin+ placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>simvastatin 20 mg daily Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin and micronized trans-resveratrol</intervention_name>
    <arm_group_label>Simvastatin + resveratrol</arm_group_label>
    <arm_group_label>simvastatin+ placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PCOs

          -  insulin resistance

          -  normal prolactin, TSH, 17 OH progesterone No evidence of androgen producing
             malignancy, Cushing's syndrome or acromegaly

        Exclusion Criteria:

          -  use of oral contraceptives and/or other steroid hormones 3 months prior to the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Infertility and Reproductive Endocrinology, Department of Gynecology and Obsterics</name>
      <address>
        <city>Poznan</city>
        <zip>60-184</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Banaszewska, Md Ph D</last_name>
      <phone>+48618419412</phone>
      <email>bbeata48@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Robert Z Spaczynski, Md PhD Prof</last_name>
      <phone>+48618419412</phone>
      <email>rspaczynski@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Leszek A Pawelczyk, MD PhD Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoni J Duleba, MD Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Poznan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Beata Banaszewska</investigator_full_name>
    <investigator_title>MD PhD Ass Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

